Assess propofol effects on brain
- Trial ID
- NCT05895019
- Official Title
- Effects of Propofol on Brain Function in Patients With Parkinson's Disease
- Goal
- Assess propofol effects on brain
- Status
- RECRUITING
- Sponsor
- Beijing Tiantan Hospital
- Study Type
- OBSERVATIONAL
- Enrollment
- 600 participants
- Conditions
- PD - Parkinson's Disease
- Interventions
- Propofol
Plain-Language Summary
They are looking at how propofol, the common anesthetic that enhances GABA-A activity and quiets brain electrical signals, changes brain function in people with Parkinson's, especially during procedures like bilateral deep brain stimulation. It's an observational study where propofol is given during surgery and researchers record how it alters neuronal activity; propofol does not boost or block dopamine like levodopa, but by suppressing neural firing it can change the brain signals clinicians rely on for DBS and may affect how symptoms or recordings appear under anesthesia. The trial enrolls adults 18 to 80 years old, ASA class I to III, including people with primary or genetic PD who still respond well to levodopa and are scheduled for bilateral DBS, plus a comparison group of adults without neurological disease having non-neurosurgical, non-cardiac operations, with exclusions for severe sleep apnea, BMI over 30, difficult airways, serious organ failure, or prior major brain injury.
Locations
- Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Propofol. They are looking at how propofol, the common anesthetic that enhances GABA-A activity and quiets brain electrical signals, changes brain function in people with Parkinson's, especially during procedures like bilateral deep brain stimulation. It's an observational study where propofol is given during surgery and researchers record how it alters neuronal activity; propofol does not boost or block dopamine like levodopa, but by suppressing neural firing it can change the brain signals clinicians rely on for DBS and may affect how symptoms or recordings appear under anesthesia. The trial enrolls adults 18 to 80 years old, ASA class I to III, including people with primary or genetic PD who still respond well to levodopa and are scheduled for bilateral DBS, plus a comparison group of adults without neurological disease having non-neurosurgical, non-cardiac operations, with exclusions for severe sleep apnea, BMI over 30, difficult airways, serious organ failure, or prior major brain injury.
- Who can participate?
- Participants must be between 18 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 4 months.